Krka d. d Valuation
Is KRK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of KRK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: KRK (PLN550) is trading below our estimate of fair value (PLN771.63)
Significantly Below Fair Value: KRK is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for KRK?
Other financial metrics that can be useful for relative valuation.
| What is KRK's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €3.88b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.9x |
| Enterprise Value/EBITDA | 6.9x |
| PEG Ratio | 2.9x |
Price to Earnings Ratio vs Peers
How does KRK's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 43.1x | ||
BGD Biogened | 15.1x | n/a | zł63.4m |
IPCALAB Ipca Laboratories | 60.7x | 35.5% | ₹342.8b |
TAIP.Y Taisho Pharmaceutical Holdings | 71.8x | 18.2% | US$3.9b |
KLBF Kalbe Farma | 24.9x | 11.4% | Rp68.9t |
KRK Krka d. d | 12.4x | 4.3% | zł3.9b |
Price-To-Earnings vs Peers: KRK is good value based on its Price-To-Earnings Ratio (12.4x) compared to the peer average (43.1x).
Price to Earnings Ratio vs Industry
How does KRK's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: KRK is good value based on its Price-To-Earnings Ratio (12.4x) compared to the European Pharmaceuticals industry average (24.8x).
Price to Earnings Ratio vs Fair Ratio
What is KRK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 12.4x |
| Fair PE Ratio | 45.9x |
Price-To-Earnings vs Fair Ratio: KRK is good value based on its Price-To-Earnings Ratio (12.4x) compared to the estimated Fair Price-To-Earnings Ratio (45.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | zł550.00 | zł574.89 +4.5% | 11.8% | zł645.27 | zł490.40 | n/a | 5 |
| Apr ’25 | zł558.00 | zł574.89 +3.0% | 11.8% | zł645.27 | zł490.40 | n/a | 5 |
| Mar ’25 | zł520.00 | zł580.12 +11.6% | 11.8% | zł651.14 | zł494.87 | n/a | 5 |
| Feb ’25 | zł500.00 | zł541.75 +8.4% | 13.5% | zł652.19 | zł458.71 | n/a | 5 |
| Jan ’25 | zł483.00 | zł518.75 +7.4% | 9.4% | zł600.72 | zł457.59 | n/a | 5 |
| Dec ’24 | zł466.00 | zł523.27 +12.3% | 9.3% | zł604.94 | zł460.81 | n/a | 5 |
| Nov ’24 | zł472.00 | zł554.62 +17.5% | 9.3% | zł641.19 | zł488.42 | n/a | 5 |
| Oct ’24 | zł500.00 | zł522.46 +4.5% | 6.3% | zł557.71 | zł470.71 | n/a | 5 |
| Sep ’24 | zł472.00 | zł522.46 +10.7% | 6.3% | zł557.71 | zł470.71 | n/a | 5 |
| Aug ’24 | zł504.00 | zł522.46 +3.7% | 6.3% | zł557.71 | zł470.71 | n/a | 5 |
| Jul ’24 | zł518.00 | zł523.40 +1.0% | 7.5% | zł567.43 | zł478.91 | n/a | 5 |
| Jun ’24 | zł504.00 | zł523.40 +3.8% | 7.5% | zł567.43 | zł478.91 | n/a | 5 |
| May ’24 | zł532.00 | zł532.83 +0.2% | 10.5% | zł589.94 | zł443.64 | zł540.00 | 5 |
| Apr ’24 | zł510.00 | zł532.83 +4.5% | 10.5% | zł589.94 | zł443.64 | zł558.00 | 5 |
| Mar ’24 | zł496.00 | zł532.83 +7.4% | 10.5% | zł589.94 | zł443.64 | zł520.00 | 5 |
| Feb ’24 | zł502.00 | zł492.54 -1.9% | 6.4% | zł541.51 | zł442.63 | zł500.00 | 5 |
| Jan ’24 | zł435.00 | zł490.15 +12.7% | 6.4% | zł539.62 | zł440.31 | zł483.00 | 5 |
| Dec ’23 | zł445.00 | zł495.36 +11.3% | 5.3% | zł541.21 | zł460.41 | zł466.00 | 5 |
| Nov ’23 | zł434.00 | zł498.62 +14.9% | 6.4% | zł551.39 | zł469.06 | zł472.00 | 4 |
| Oct ’23 | zł420.00 | zł521.31 +24.1% | 12.7% | zł634.95 | zł471.41 | zł500.00 | 4 |
| Sep ’23 | zł463.00 | zł551.29 +19.1% | 14.1% | zł631.27 | zł468.67 | zł472.00 | 4 |
| Aug ’23 | zł469.00 | zł551.29 +17.5% | 14.1% | zł631.27 | zł468.67 | zł504.00 | 4 |
| Jul ’23 | zł453.00 | zł523.16 +15.5% | 17.4% | zł613.71 | zł404.49 | zł518.00 | 4 |
| Jun ’23 | zł420.00 | zł523.16 +24.6% | 17.4% | zł613.71 | zł404.49 | zł504.00 | 4 |
| May ’23 | zł417.00 | zł557.38 +33.7% | 11.0% | zł615.56 | zł466.33 | zł532.00 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.